NDAORALSOLUTION
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
91
Data completeness
5/8 — Partial
RINVOQ LQ (upadacitinib) by AbbVie is janus kinase inhibitors [moa]. Approved for rheumatoid arthritis, atopic dermatitis, ulcerative colitis and 1 more indications. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RINVOQ LQ is an oral Janus Kinase (JAK) inhibitor solution formulation of upadacitinib approved in April 2024 for rheumatoid arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. It works by selectively inhibiting JAK enzymes to reduce inflammatory cytokine signaling. The LQ formulation represents a line extension of the established RINVOQ tablet, targeting improved patient convenience and adherence.
Growth10.5 years to LOE
As a 2024 launch in growth phase with strong parent franchise (RINVOQ generating $976M), the team is expanding rapidly with focus on market penetration and indication expansion.
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Indications (4)
Worked on RINVOQ LQ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.